Higher-dose palopegteriparatide treatment for adults with hypoparathyroidism.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 randomized trial enrolls adults who are already taking palopegteriparatide at or above 30 µg/day and continues subcutaneous palopegteriparatide for 78 weeks. Participants will be individually and progressively titrated to an optimal dose at pre-specified dose levels above 30 µg/day. The trial collects safety and efficacy data to provide additional evidence about using doses greater than 30 µg/day. All laboratory confirmations and dosing adjustments are performed according to the protocol before and during randomization.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Males and females, ≥18 years of age at the time of providing informed consent
2. Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks
3. Receiving doses of palopegteriparatide at or above 30 µg/day

   For individuals receiving 30 µg/day: evidence that dose is insufficient to keep serum calcium in the normal range, defined as:

   Documented hypocalcemia within 12 weeks prior to Screening; and/or Standing dose of calcitriol ≥0.25 μg/day, and / or (elemental) calcium ≥1500 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening

   For individuals receiving 33 µg/day or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium
4. Confirmation of laboratory parameters (Central or Local) within 2 weeks of screening visit and prior to randomization:

25(OH) vitamin D levels of ≥ 20 ng/mL (≥49 nmol/L) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg/dL (≥0.53 mmol/L) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range

* Albumin-adjusted sCa 7.8 - 10.6 mg/dL (or 1.95 - 2.64 mmol/L)
* Ionized sCa 4.40 - 5.29 mg/dL (1.10 - 1.32 mmol/L)

  5\. BMI 17- 40 kg/m2 at Screening

  6\. If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand

  7\. eGFR ≥30 mL/min/1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula

Exclusion criteria

1. Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP
3. Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin \>30 µg/day, or systemic corticosteroids (other than as replacement therapy)
4. Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1
5. Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an investigational trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening
6. Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening
7. Use of denosumab or romosozumab within 2 years prior to Screening. Use of raloxifene within 4 weeks prior to Screening.
8. Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening.
9. Increased risk for osteosarcoma
10. Women who are pregnant, intend to become pregnant, or are lactating
11. Diagnosed drug or alcohol dependence within 3 years prior to Screening
12. Chronic or severe cardiac disease within 26 weeks prior to Screening
13. Cerebrovascular accident within 5 years prior to Screening.
14. Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout
15. Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening.
16. Known allergy or sensitivity to PTH or any of the excipients \[metacresol, mannitol, succinic acid, NaOH/(HCl)\] of the investigational product

Where it's running

• Ascendis Pharma Investigational Site
  Greeley, Colorado, United States Recruiting
• Ascendis Pharma Investigational Site
  Chicago, Illinois, United States Recruiting
• Ascendis Pharma Investigational Site
  Minneota, Minnesota, United States Recruiting
• Ascendis Pharma Investigational Site
  Reno, Nevada, United States Recruiting
• Ascendis Pharma Investigational Site
  New Brunswick, New Jersey, United States Recruiting
• Ascendis Pharma Investigational Site
  New York, New York, United States Recruiting

Study contacts

• Study coordinator: Ascendis Registry Inquiries
• Email: asnd_registryinquiries@ascendispharma.com
• Phone: +4561161658

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• German Hypoparathyroidism Registry

  This registry in Germany collects information from adults with chronic hypoparathyroidism or pseudohypoparathyroidism to better understand how the condition affects people over time and to support future research.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857460

• Encaleret for Chronic Hypoparathyroidism: Testing if it helps symptoms and safety

  This study tests whether taking encaleret pills can help people with chronic hypoparathyroidism, while being safe and tolerable.

  Recruiting at 5 sites Phase 3 Calcilytix Therapeutics, Inc., a BridgeBio company · Reno, Nevada and 4 other locations · NCT07805356

• Palopegteriparatide in adolescents with long-term hypoparathyroidism

  This study tests whether a once-daily palopegteriparatide shot helps adolescents with long‑standing hypoparathyroidism and whether it’s safe for them.

  Recruiting at 3 sites Phase 3 Ascendis Pharma A/S · Bron and 2 other locations · NCT07706764

• Canvuparatide vs placebo in adults with hypoparathyroidism

  This study tests whether weekly canvuparatide can help adults with hypoparathyroidism feel better and keep calcium levels steady compared with a placebo.

  Recruiting at 22 sites Phase 3 MBX Biosciences · Englewood, Colorado and 21 other locations · NCT07699471

• AMX0035 in adults with Type 1 Diabetes

  This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.

  Recruiting Phase 2 University of Washington · Seattle, Washington and 1 other locations · NCT07699380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.